Table 1 Baseline characteristics of the second follow-up data of HCC patients treated with TACE
Characteristics | ΔLDH (U/L) | P# value | P$ value | ||
|---|---|---|---|---|---|
> − 80, < 80 | ≤ − 80 | ≥ 80 | |||
N | 444 | 217 | 88 | 0.997 | 0.639 |
Age (years, median ± SD) | 52.1 ± 12.2 | 53.0 ± 12.4 | 51.3 ± 11.4 | ||
< 55 | 225 (50.7%) | 110 (50.7%) | 47 (53.4%) | ||
≥ 55 | 219 (49.3%) | 107 (49.3%) | 41 (46.6%) | ||
Gender | 0.292 | 0.436 | |||
Male | 408 (91.9%) | 194 (89.4%) | 83 (94.3%) | ||
Female | 36 (8.1%) | 23 (10.6%) | 5 (5.7%) | ||
PS score | 0.001 | 0.001 | |||
0 | 384 (86.5%) | 117 (54%) | 64 (72.7%) | ||
1 | 60 (13.5%) | 40 (18.4%) | 24 (17.3%) | ||
Diameter of main tumour (cm) | 0.035 | < 0.001 | |||
< 5 | 200 (45.0%) | 79 (36.4%) | 16 (18.2%) | ||
≥ 5 | 244 (55.0%) | 138 (63.6%) | 72 (81.8%) | ||
AFP (ng/mL) | 0.205 | 0.001 | |||
< 25 | 209 (47.1%) | 93 (42.9%) | 23 (26.1%) | ||
≥ 25 | 214 (48.2%) | 118 (54.4%) | 58 (65.9%) | ||
Hgb (g/L) | 0.567 | 0.129 | |||
< 120 | 108 (24.3%) | 49 (22.6%) | 28 (31.8%) | ||
≥ 120 | 297 (66.9%) | 151 (69.6%) | 52 (59.1%) | ||
WBC (109/L) | 0.072 | < 0.001 | |||
< 11 | 380 (85.6%) | 184 (84.8%) | 65 (73.9%) | ||
≥ 11 | 22 (5.0%) | 19 (8.8%) | 15 (17.0%) | ||
No. of intrahepatic lesions | 0.021 | < 0.001 | |||
0 | 198 (44.6%) | 79 (36.4%) | 16 (18.2%) | ||
≤ 3 | 106 (23.9%) | 46 (21.2%) | 17 (19.3%) | ||
> 3 | 140 (31.5%) | 92 (42.4%) | 55 (62.5%) | ||
Location of lesions | 0.048 | < 0.001 | |||
None | 198 (4.3%) | 79 (36.4%) | 16 (18.2%) | ||
Left/right | 109 (24.5%) | 51 (23.5%) | 26 (29.5%) | ||
Both | 137 (30.9%) | 87 (40.1%) | 46 (52.3%) | ||
Child–Pugh class | |||||
A | 344 (77.5%) | 178 (82.0%) | 48 (54.5%) | 0.178 | < 0.001 |
B | 100 (22.5%) | 39 (18.0%) | 40 (45.5%) | ||